Astrimmune Ltd.

December deals with Micromet and CancerVax have accelerated Serono's move into oncology. The firm's strengths in biologics development, marketing, and manufacturing should match up well with the requi

Faster, more accurate identification of tumor-associated peptides Immatics Biotechnologies GMBH identifies tumor-associated peptides by directly measuring their presence in cancer tissue and then

When Micromet's development partner for lead anti-carcinoma antibody MT201 was bought by Cell Therapeutics in mid-2003, the German biotech was forced to restructure significantly in order to continue

Engineering sweeter antibodies GlycArt Biotechnology AG aims to boost a natural mechanism of action of therapeutic antibodies to treat cancer and autoimmune diseases. Unlike most advances in antib